M
586.21
6.32 (1.09%)
| Penutupan Terdahulu | 579.89 |
| Buka | 574.89 |
| Jumlah Dagangan | 205,033 |
| Purata Dagangan (3B) | 349,443 |
| Modal Pasaran | 13,313,661,952 |
| Harga / Jualan (P/S) | 17.88 |
| Harga / Buku (P/B) | 21.67 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2025 |
| Margin Keuntungan | -123.38% |
| Margin Operasi (TTM) | -57.79% |
| EPS Cair (TTM) | -17.83 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 16.85% |
| Nisbah Semasa (MRQ) | 5.91 |
| Aliran Tunai Operasi (OCF TTM) | -395.31 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -274.11 M |
| Pulangan Atas Aset (ROA TTM) | -25.56% |
| Pulangan Atas Ekuiti (ROE TTM) | -50.16% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Madrigal Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.2
| Konsensus Penganalisis | -1.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | -0.20 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 7.73% |
| % Dimiliki oleh Institusi | 108.28% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Rtw Investments, Lp | 30 Sep 2025 | 1,993,687 |
| Paulson & Co. Inc. | 30 Sep 2025 | 1,907,523 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 650.00 (Oppenheimer, 10.88%) | Beli |
| Median | 573.50 (-2.17%) | |
| Rendah | 445.00 (B of A Securities, -24.09%) | Pegang |
| Purata | 571.13 (-2.57%) | |
| Jumlah | 7 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 490.67 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Nov 2025 | 620.00 (5.76%) | Beli | 547.96 |
| 11 Nov 2025 | 568.00 (-3.11%) | Beli | 541.50 | |
| Oppenheimer | 20 Nov 2025 | 650.00 (10.88%) | Beli | 542.12 |
| 10 Oct 2025 | 590.00 (0.65%) | Beli | 429.60 | |
| Truist Securities | 19 Nov 2025 | 640.00 (9.18%) | Beli | 555.60 |
| 15 Oct 2025 | 580.00 (-1.06%) | Beli | 433.45 | |
| Canaccord Genuity | 13 Nov 2025 | 587.00 (0.13%) | Beli | 514.93 |
| 12 Sep 2025 | 526.00 (-10.27%) | Beli | 432.22 | |
| Citizens | 05 Nov 2025 | 527.00 (-10.10%) | Beli | 475.87 |
| B of A Securities | 03 Nov 2025 | 445.00 (-24.09%) | Pegang | 412.35 |
| Piper Sandler | 15 Oct 2025 | 540.00 (-7.88%) | Beli | 433.45 |
| B. Riley Securities | 29 Sep 2025 | 560.00 (-4.47%) | Beli | 443.10 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HUNTSMAN CAROLE | - | 547.96 | -1,958 | -1,072,906 |
| Jumlah Keseluruhan Kuantiti Bersih | -1,958 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,072,906 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 547.96 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HUNTSMAN CAROLE | Pegawai | 21 Nov 2025 | Jual (-) | 894 | 547.96 | 489,876 |
| HUNTSMAN CAROLE | Pegawai | 21 Nov 2025 | Jual automatik (-) | 1,064 | 547.96 | 583,029 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |